Bernstein initiated coverage of Crispr Therapeutics with a Market Perform rating and $44 price target. The analyst expects the Exa-cel launch to outperform, but says 60% of the value of this program has already been monetized through the Vertex deal. In oncology, Crispr needs to improve its cell persistence before it can have a competitive CD19 product, the analyst tells investors in a research note. The firm believes the shares are currently fairly valued.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $55 from $63 at Citi
- Crispr Therapeutics initiated with a Buy at Bryan Garnier
- CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
- Crispr Therapeutics CFO Brendan Smith to depart, Raju Prasad to succeed
- CRISPR Therapeutics Announces Transition of Chief Financial Officer
